Literature DB >> 15181327

Seroepidemiological and microbiological study of brucellosis in Kuwait.

Ts Dimitrov1, D Panigrahi, M Emara, F Awni, R Passadilla.   

Abstract

OBJECTIVE: The primary objective of the study was to determine the prevalence of brucellosis and the antimicrobial susceptibility pattern of local Brucellae isolates in the Infectious Diseases Hospital, Kuwait. SUBJECTS AND METHODS: A single serum sample was collected from each of 1,836 patients of different nationalities from January 2000 to December 2001. Any patient with a provisional diagnosis of fever or brucellosis had a standard tube agglutination (STA) test for the quantitation of Brucella antibodies. Blood cultures were done in 166 of 455 patients with significant STA titers, using the Bactec system. Antimicrobial susceptibility testing of 123 isolates of Brucella spp. was done against 8 antimicrobial agents.
RESULTS: A total of 455 serum samples (24.8%) having an STA titer of > or =1:160 were presumptively diagnosed as cases of brucellosis. The peak isolation was in April and May. Brucella spp. were isolated from 123 blood cultures (74.1%). The blood culture isolation rate was significantly higher in patients with an STA titer of >/=1:1,280 than in those with an STA titer of </=1:160 (p < 0.05). Antimicrobial susceptibility testing showed good in vitro activity of tetracycline, gentamicin, amikacin, streptomycin and ciprofloxacin against all isolates. Azithromycin had good anti-Brucella activity against only 42% of the isolates, while rifampicin and trimethoprim-sulfamethoxazole showed low in vitro anti-Brucella activity against 8 and 25% of the isolates, respectively.
CONCLUSION: Brucellosis is quite common in Kuwait. Kuwaiti and Bangladeshi nationals were most affected. Significant titers on the STA test were detected in 24.8% of serum samples. Good in vitro activity against all isolates was found with tetracycline, gentamicin, amikacin, ciprofloxacin and streptomycin, and low activity with azithromycin, rifampicin and trimethoprim-sulfamethoxazole. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181327     DOI: 10.1159/000078319

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  8 in total

1.  Antimicrobial susceptibility of Brucella melitensis isolates in Peru.

Authors:  Ryan C Maves; Rosa Castillo; Alfredo Guillen; Benjamin Espinosa; Rina Meza; Nereyda Espinoza; Gladys Núñez; Luis Sánchez; Jesús Chacaltana; David Cepeda; Sofía González; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

Review 2.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Effect of Medium pH on Antibiotic Activity against Syrian Brucella spp. Isolates.

Authors:  Ayman Al-Mariri; Mazen Safi
Journal:  Iran J Med Sci       Date:  2013-09

4.  Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis.

Authors:  Rohaidah Hashim; Norazah Ahmad; Jama'ayah Mohamed Zahidi; B Y Tay; Azura Mohd Noor; Sakina Zainal; Hazwani Hamzah; S H Hamzah; T S Chow; P S Wong; K N Leong
Journal:  Int J Microbiol       Date:  2014-07-10

5.  Species identification and molecular typing of human Brucella isolates from Kuwait.

Authors:  Abu S Mustafa; Nazima Habibi; Amr Osman; Faraz Shaheed; Mohd W Khan
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

6.  Efficacy evaluation of some antibiotics against syrian brucella spp isolates, in vitro.

Authors:  Mazen Safi; Ayman Al-Mariri
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

7.  Prevalence and risk factors of brucellosis among febrile patients attending a community hospital in south western Uganda.

Authors:  Richard Migisha; Yap Boum; Anne-Laure Page; Amaia Zúñiga-Ripa; Raquel Conde-Álvarez; Fred Bagenda; Maryline Bonnet
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

8.  A randomized, comparative study of dual therapy (doxycycline-rifampin) versus triple therapy (doxycycline-rifampin-levofloxacin) for treating acute/subacute brucellosis.

Authors:  Ahmad Hasanain; Reem Mahdy; Asmaa Mohamed; Mostafa Ali
Journal:  Braz J Infect Dis       Date:  2016-04-14       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.